Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clariane SEXPAR:CLARI -4.22%58 3-1 Month Momentum % is 0.20% as of Sep. 21, 2026. GuruFocus rates XPAR:CLARI with a GF Score™ of 58/100 and a GF Value™ of €2.50 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 670 Healthcare Providers & Services companies, Clariane SE ranks worse than 50.6% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-21), Clariane SE's 3-1 Month Momentum % is 0.20%.
The industry rank for Clariane SE's 3-1 Month Momentum % or its related term are showing as below:
XPAR:CLARI's 3-1 Month Momentum % is ranked worse than 50.6% of 670
companies
in the Healthcare Providers & Services industry
Industry Median: 0.56
vs XPAR:CLARI: 0.20
Clariane SE (XPAR:CLARI) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Clariane SE 3-1 Month Momentum % Related Terms
XPAR:CLARI vs HCA, THC, EHC: 3-1 Month Momentum % Comparison
For the Medical Care Facilities subindustry, Clariane SE's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clariane SE 3-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Clariane SE's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Clariane SE's 3-1 Month Momentum % falls into.
Clariane SE (XPAR:CLARI) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clariane SE (XPAR:CLARI) has a 3-1 Month Momentum % of 0.20% as of Sep. 21, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Clariane SE and its competitors. According to the industry distribution chart, Clariane SE ranks #339 out of 670 companies in the Healthcare Providers & Services industry, placing it in the top 50.6%.
Is Clariane SE's 3-1 Month Momentum % too high?
Clariane SE's current 3-1 Month Momentum % is 0.20%. The Healthcare Providers & Services industry median 3-1 Month Momentum % is 0.56. Clariane SE's value of 0.20% is 64.3% below this industry median. Based on the distribution chart, Clariane SE ranks #339 out of 670 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Clariane SE has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clariane SE's 3-1 Month Momentum % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Clariane SE ranks #339 out of 670 companies for 3-1 Month Momentum %. This places Clariane SE in the lower half of its industry. The industry median 3-1 Month Momentum % is 0.56. Clariane SE's value of 0.20% is 64.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Healthcare Providers & Services company?
The median 3-1 Month Momentum % among Healthcare Providers & Services companies is 0.56, based on 670 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clariane SE's current 3-1 Month Momentum % of 0.20% is 64.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Clariane SE and its competitors. For the Healthcare Providers & Services industry, the median 3-1 Month Momentum % is 0.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clariane SE's current 3-1 Month Momentum % is 0.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clariane SE stock overvalued right now?
Based on GuruFocus' analysis, Clariane SE (XPAR:CLARI) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.50, compared to a current price of €3.82 — trading 52.6% above its estimated fair value. The current 3-1 Month Momentum % is 0.20% and 64.3% below the Healthcare Providers & Services industry median of 0.56. Clariane SE's overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Clariane SE (XPAR:CLARI), the current 3-1 Month Momentum % is 0.20% as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clariane SE (XPAR:CLARI) Overvalued in 2026?
Based on GuruFocus' analysis, Clariane SE stock appears to be overvalued.
The current stock price of €3.82 is trading 52.6% above its estimated GF Value™ of €2.50.
GuruFocus considers Clariane SE to be Significantly Overvalued.
Key valuation signals for XPAR:CLARI:
3-1 Month Momentum %: 0.20%
GF Value™: €2.50 vs. price of €3.82 (52.6% above fair value)
Industry Position: 64.3% below the Healthcare Providers & Services median (#339 of 670)
No single metric tells the full story. See the XPAR:CLARI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clariane SE is a specialist in non-acute care and operates in two main areas: long-term care, through two forms of support, medicalized nursing homes offering specialty facilities accommodation and care for vulnerable older people and alternative living solutions, and specialty care activities such as specialty and post-acute , mental health and a number of medical, surgical and obstetrics clinics. Its segments include France, Germany, Benelux, Italy and Spain.
58GF Score
Get the complete analysis for XPAR:CLARI
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:CLARI has been successfully added to your 
